

TMSPHASPSM01: MSc Pharmacogenetics and Stratified Medicine

TMSPHASPSM01□

View Online



[1]

Abou-Sleiman, P.M. et al. 2006. Expanding insights of mitochondrial dysfunction in Parkinson's disease. *Nature Reviews Neuroscience*. 7, 3 (Mar. 2006), 207–219. DOI:<https://doi.org/10.1038/nrn1868>.

[2]

Altshuler, D. et al. 2008. Genetic Mapping in Human Disease. *Science*. 322, 5903 (Nov. 2008), 881–888. DOI:<https://doi.org/10.1126/science.1156409>.

[3]

Antonarakis, S.E. and Beckmann, J.S. 2006. Mendelian disorders deserve more attention. *Nature Reviews Genetics*. 7, 4 (Mar. 2006), 277–282. DOI:<https://doi.org/10.1038/nrg1826>.

[4]

Atherosclerosis — An Inflammatory Disease — *NEJM*: .

[5]

Balding, D.J. 2006. A tutorial on statistical methods for population association studies. *Nature Reviews Genetics*. 7, 10 (Oct. 2006), 781–791. DOI:<https://doi.org/10.1038/nrg1916>.

[6]

Bishop, M. et al. 2007. Handbook of statistical genetics. John Wiley.

[7]

Botstein, D. and Risch, N. 2003. Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. *Nature Genetics*. 33, 3s (Mar. 2003), 228–237. DOI:<https://doi.org/10.1038/ng1090>.

[8]

Bras, J.M. and Singleton, A. 2009. Genetic susceptibility in Parkinson's disease. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*. 1792, 7 (Jul. 2009), 597–603. DOI:<https://doi.org/10.1016/j.bbadis.2008.11.008>.

[9]

Brinkman, R.R. et al. 2006. Human monogenic disorders — a source of novel drug targets. *Nature Reviews Genetics*. 7, 4 (Mar. 2006), 249–260. DOI:<https://doi.org/10.1038/nrg1828>.

[10]

Burton, Paul et al. 2011. An introduction to genetic epidemiology. Policy Press.

[11]

Capecchi, M.R. 2005. Essay: Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century. *Nature Reviews Genetics*. 6, 6 (Jun. 2005), 507–512. DOI:<https://doi.org/10.1038/nrg1619>.

[12]

Daly, A.K. 2010. Genome-wide association studies in pharmacogenomics. *Nature Reviews Genetics*. 11, 4 (Apr. 2010), 241–246. DOI:<https://doi.org/10.1038/nrg2751>.

[13]

Foulkes, Andrea S. 2009. Applied statistical genetics with R: for population-based association studies. Springer.

[14]

Gibb, Alasdair J. et al. 2011. Textbook of receptor pharmacology. CRC Press.

[15]

Hall, I.P. and Pirmohamed, M. 2006. Pharmacogenetics. Taylor & Francis.

[16]

Hansson, G.K. and Libby, P. 2006. The immune response in atherosclerosis: a double-edged sword. *Nature Reviews Immunology*. 6, 7 (Jun. 2006), 508–519.
DOI:<https://doi.org/10.1038/nri1882>.

[17]

Hirschhorn, J.N. and Daly, M.J. 2005. Genome-wide association studies for common diseases and complex traits. *Nature Reviews Genetics*. 6, 2 (Feb. 2005), 95–108.
DOI:<https://doi.org/10.1038/nrg1521>.

[18]

Holmes, M.V. 2011. CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular EventsA Systematic Review and Meta-analysis. *JAMA: The Journal of the American Medical Association*. 306, 24 (Dec. 2011).
DOI:<https://doi.org/10.1001/jama.2011.1880>.

[19]

Holmes, M.V. et al. 2009. Fulfilling the Promise of Personalized Medicine? Systematic Review and Field Synopsis of Pharmacogenetic Studies. *PLoS ONE*. 4, 12 (Dec. 2009).
DOI:<https://doi.org/10.1371/journal.pone.0007960>.

[20]

Holmes, M.V. et al. 2009. Fulfilling the Promise of Personalized Medicine? Systematic Review and Field Synopsis of Pharmacogenetic Studies. PLoS ONE. 4, 12 (Dec. 2009). DOI:<https://doi.org/10.1371/journal.pone.0007960>.

[21]

Humphries, S.E. and Hingorani, A. 2006. Pharmacogenetics: Progress, pitfalls and clinical potential for coronary heart disease. Vascular Pharmacology. 44, 2 (Feb. 2006), 119–125. DOI:<https://doi.org/10.1016/j.vph.2005.10.003>.

[22]

Kathiresan, S. et al. 2009. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nature Genetics. 41, 3 (Feb. 2009), 334–341. DOI:<https://doi.org/10.1038/ng.327>.

[23]

Kenakin, Terrence P. 2009. A pharmacology primer: theory, applications, and methods. Elsevier Academic Press.

[24]

Kirkwood, Betty R. et al. 2003. Essential medical statistics. Blackwell Science.

[25]

Lee, A.J.X. and Swanton, C. 2012. Tumour heterogeneity and drug resistance: Personalising cancer medicine through functional genomics. Biochemical Pharmacology. 83, 8 (Apr. 2012), 1013–1020. DOI:<https://doi.org/10.1016/j.bcp.2011.12.008>.

[26]

Lefkowitz, R.J. 2004. Historical review: A brief history and personal retrospective of seven-transmembrane receptors. Trends in Pharmacological Sciences. 25, 8 (Aug. 2004), 413–422. DOI:<https://doi.org/10.1016/j.tips.2004.06.006>.

[27]

Lesk, Arthur M. 2008. Introduction to bioinformatics. Oxford University Press.

[28]

McCarthy, M.I. et al. 2008. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. *Nature Reviews Genetics*. 9, 5 (May 2008), 356–369.
DOI:<https://doi.org/10.1038/nrg2344>.

[29]

Neale, Benjamin M. and International Workshop of Twin and Family Studies 2008. *Statistical genetics: gene mapping through linkage and association*. Taylor & Francis.

[30]

Neubig, R.R. 2003. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology. *Pharmacological Reviews*. 55, 4 (Dec. 2003), 597–606.
DOI:<https://doi.org/10.1124/pr.55.4.4>.

[31]

O'Connor, T.P. and Crystal, R.G. 2006. Genetic medicines: treatment strategies for hereditary disorders. *Nature Reviews Genetics*. 7, 4 (Apr. 2006), 261–276.
DOI:<https://doi.org/10.1038/nrg1829>.

[32]

Orengo, Christine Ann et al. 2003. *Bioinformatics: genes, proteins and computers*. BIOS.

[33]

Ropers, H.-H. 2007. New Perspectives for the Elucidation of Genetic Disorders. *The American Journal of Human Genetics*. 81, 2 (Aug. 2007), 199–207.
DOI:<https://doi.org/10.1086/520679>.

[34]

Seifert, R. and Wenzel-Seifert, K. 2002. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. *Naunyn-Schmiedeberg's Archives of Pharmacology*. 366, 5 (Nov. 2002), 381-416. DOI:<https://doi.org/10.1007/s00210-002-0588-0>.

[35]

Sham, P. 2007. *Statistics in human genetics*. Wiley.

[36]

Table of contents : *Nature Reviews Genetics Focus on Monogenic disorders* : .

[37]

Thomas, Duncan C. 2004. *Statistical methods in genetic epidemiology*. Oxford University Press.

[38]

Thompson, A.J. et al. 2010. The structural basis of function in Cys-loop receptors. *Quarterly Reviews of Biophysics*. 43, 04 (Nov. 2010), 449-499. DOI:<https://doi.org/10.1017/S0033583510000168>.

[39]

Yusuf, S. et al. 2004. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *The Lancet*. 364, 9438 (Sep. 2004), 937-952. DOI:[https://doi.org/10.1016/S0140-6736\(04\)17018-9](https://doi.org/10.1016/S0140-6736(04)17018-9).

[40]

Zvelebil, Marketa J. and Baum, Jeremy O. 2008. *Understanding bioinformatics*. Garland Science.

[41]

New Perspectives for the Elucidation of Genetic Disorders. DOI:<https://doi.org/520679>.